Rozlytrek vs. Vitrakvi

• Are Rozlytrek and Vitrakvi the Same Thing?
• What Are Possible Side Effects of Rozlytrek?
• What Are Possible Side Effects of Vitrakvi?
• What Is Rozlytrek?
• What Is Vitrakvi?
• What Drugs Interact with Rozlytrek?
• What Drugs Interact with Vitrakvi?
• How Should Rozlytrek Be Taken?
• How Should Vitrakvi Be Taken?

Rozlytrek (entrectinib) and Vitrakvi (larotrectinib) are kinase inhibitors used to treat adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.

Rozlytrek is also used to treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.

Side effects of Rozlytrek and Vitrakvi that are similar include fatigue, constipation, dizziness, diarrhea, nausea, shortness of breath, muscle pain, weight gain, cough, vomiting, fever, and joint pain.

Side effects of Rozlytrek that are different from Vitrakvi include changes in taste, fluid retention (edema), impaired sense of touch, cognitive impairment, and vision disorders (blurred vision, light sensitivity, double vision, visual impairment, flashes of light, cataracts, and floaters).

Side effects of Vitrakvi that are different from Rozlytrek include anemia, increased AST, increased ALT, swelling of extremities, abdominal pain, headache, stuffy nose, muscle weakness, back pain, pain in extremities, loss of appetite, and high blood pressure (hypertension).

Both Rozlytrek and Vitrakvi may interact with grapefruit and grapefruit products and strong or moderate CYP3A inhibitors or inducers.

Rozlytrek may also interact with medications that prolong the QT/QTc interval.

Common side effects of Rozlytrek include:

• fatigue,
• constipation,
• changes in taste,
• fluid retention/swelling (edema),
• dizziness,
• diarrhea,
• nausea,
• impaired sense of touch,
• shortness of breath,
• muscle pain,
• cognitive impairment,
• weight gain,
• cough,
• vomiting,
• fever,
• joint pain, and
• vision disorders
• blurred vision,
• light sensitivity,
• double vision,
• visual impairment,
• flashes of light,
• cataracts, and
• floaters

Side effects of Vitrakvi nclude<:/p>

• fatigue,
• nausea,
• dizziness,
• vomiting,
• anemia,
• increased AST,
• cough,
• increased ALT,
• constipation,
• diarrhea,
• fever,
• swelling of extremities,
• abdominal pain,
• headache,
• shortness of breath,
• stuffy nose,
• weight gain,
• joint pain,
• muscle pain,
• muscle weakness,
• back pain,
• pain in extremities,
• loss of appetite, and
• high blood pressure (hypertension)

Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive; and adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.

Vitrakvi (larotrectinib) is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

Rozlytrek may interact with grapefruit and grapefruit products, strong or moderate CYP3A inhibitors or inducers, and medications that prolong the QT/QTc interval. Tell your doctor all medications and supplements you use. Rozlytrek is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Rozlytrek and for 5 weeks following the final dose. Males with female partners of reproductive potential are advised to use effective contraception during treatment with Rozlytrek and for 3 months after the final dose. It is unknown if Rozlytrek passes into breast milk. Because of the potential adverse reactions in breastfed children, breastfeeding is not recommended during treatment with Rozlytrek and for 7 days after the final dose.

Vitrakvi may interact with strong CYP3A4 inhibitors including grapefruit or grapefruit juice, strong CYP3A4 inducers including St. John's wort, and sensitive CYP3A4 substrates. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Vitrakvi; it may harm a fetus. Breastfeeding is not recommended while using Vitrakvi and for 1 week after the final dose.

The recommended dosage of Rozlytrek for ROS1-Positive non-small cell lung cancer is 600 mg orally once daily. The recommended adult dosage of Rozlytrek for NTRK gene fusion-positive solid tumors is 600 mg orally once daily. The recommended dosage of Rozlytrek is based on body surface area.

The recommended dosage of Vitrakvi in adult and pediatric patients with a body surface area of at least 1.0 meter-squared is 100 mg orally twice daily. The recommended dosage of Vitrakvi in in pediatric patients with body surface area of less than 1.0 meter-squared is 100 mg/m2 orally twice daily.